cycD1/CCND1 Cancer Research Results

cycD1/CCND1, cyclin D1 pathway: Click to Expand ⟱
Source:
Type:
Also called CCND1 Gatekeeper of Cell-Cycle Commitment
The main function of cyclin D1 is to maintain cell cycle and to promote cell proliferation. Cyclin D1 is a key regulatory protein involved in the cell cycle, particularly in the transition from the G1 phase to the S phase. It is part of the cyclin-dependent kinase (CDK) complex, where it binds to CDK4 or CDK6 to promote cell cycle progression.
Cyclin D1 is crucial for the regulation of the cell cycle. Overexpression or dysregulation of cyclin D1 can lead to uncontrolled cell proliferation, a hallmark of cancer.
Cyclin D1 is often found to be overexpressed in various cancers.
Cyclin D1 can interact with tumor suppressor proteins, such as retinoblastoma (Rb). When cyclin D1 is overexpressed, it can lead to the phosphorylation and inactivation of Rb, releasing E2F transcription factors that promote the expression of genes required for DNA synthesis and cell cycle progression.
Cyclin D1 is influenced by various signaling pathways, including the PI3K/Akt and MAPK pathways, which are often activated in cancer.
In some cancers, high levels of cyclin D1 expression have been associated with poor prognosis, making it a potential biomarker for cancer progression and treatment response.
CRC, Colorectal Cancer: Click to Expand ⟱
Colorectal cancer is a broader term that encompasses both colon and rectal cancer.
Scientific Papers found: Click to Expand⟱
2335- BBR,    Chemoproteomics reveals berberine directly binds to PKM2 to inhibit the progression of colorectal cancer
- in-vitro, CRC, HT29 - in-vitro, CRC, HCT116 - in-vivo, NA, NA
PKM2↓, Glycolysis↓, p‑STAT3↓, Bcl-2↓, cycD1/CCND1↓, TumCG↓, Ki-67↓, lactateProd↓, glucose↓,
2678- BBR,    Berberine as a Potential Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
*Inflam↓, *antiOx↑, *cardioP↑, *neuroP↑, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDC2↓, AMPK↝, mTOR↝, Casp8↑, Casp9↑, Cyt‑c↑, TumCMig↓, TumCI↓, EMT↓, MMPs↓, E-cadherin↓, Telomerase↓, *toxicity↓, GRP78/BiP↓, EGFR↓, CDK4↓, COX2↓, PGE2↓, p‑JAK2↓, p‑STAT3↓, MMP2↓, MMP9↓, GutMicro↑, eff↝, *BioAv↓, BioAv↑,
4658- BBR,    Berberine Suppresses Stemness and Tumorigenicity of Colorectal Cancer Stem-Like Cells by Inhibiting m6A Methylation
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT29
CSCs↓, TumCP↓, cycD1/CCND1↓, p27↑, P21↑, TumCCA↑, Apoptosis↑, ChemoSen↑, β-catenin/ZEB1↓, FTO↑, CD44↓, CD133↓, ChemoSen↑,
5176- BBR,    Berberine regulates AMP-activated protein kinase signaling pathways and inhibits colon tumorigenesis in mice
- vitro+vivo, CRC, HCT116 - in-vitro, CRC, SW480 - in-vitro, CRC, LoVo
TumVol↓, Ki-67↓, COX2↓, AMPK↑, mTOR↓, NF-kB↓, cycD1/CCND1↓, survivin↓, P53↑, cl‑Casp3↑, TumCP↓, Inflam↓, COX2↓, ACC↑,
2745- BetA,    Betulinic acid inhibits colon cancer cell and tumor growth and induces proteasome-dependent and -independent downregulation of specificity proteins (Sp) transcription factors
- in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vivo, NA, NA
Apoptosis↑, TumCG↓, Sp1/3/4↓, survivin↓, VEGF↓, p65↓, EGFR↓, cycD1/CCND1↓, ROS↑, MMP↓,
1169- Bos,    Boswellic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in Orthotopic Mouse Model By Downregulating Inflammatory, Proliferative, Invasive, and Angiogenic Biomarkers
- in-vivo, CRC, NA
TumCG↓, TumVol↓, Weight∅, ascitic↓, TumMeta↓, Ki-67↓, CD31↓, NF-kB↓, COX2↓, Bcl-2↓, Bcl-xL↓, IAP1↓, survivin↓, cycD1/CCND1↓, ICAM-1↓, MMP9↓, CXCR4↓, VEGF↓,
1427- Bos,    Acetyl-keto-β-boswellic acid inhibits cellular proliferation through a p21-dependent pathway in colon cancer cells
- in-vitro, CRC, HT-29 - in-vitro, CRC, HCT116 - in-vitro, CRC, LS174T
TumCG↓, TumCCA↑, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, p‑RB1↓, P21↑,
1422- Bos,    Boswellic acid exerts antitumor effects in colorectal cancer cells by modulating expression of the let-7 and miR-200 microRNA family
- in-vitro, CRC, NA - in-vivo, NA, NA
5LO↓, TumCG↓, Let-7↑, miR-200b↑, NF-kB↓, cMyc↓, cycD1/CCND1↓, MMP9↓, CXCR4↓, VEGF↓, Bcl-xL↓, survivin↓, IAP1↓, XIAP↓, TumCG↓, CDK6↓, Vim↓, E-cadherin↑,
1426- Bos,  CUR,  Chemo,    Novel evidence for curcumin and boswellic acid induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer
- in-vivo, CRC, NA - in-vitro, CRC, HCT116 - in-vitro, CRC, RKO - in-vitro, CRC, SW480 - in-vitro, RCC, SW-620 - in-vitro, RCC, HT-29 - in-vitro, CRC, Caco-2
miR-34a↑, miR-27a-3p↓, TumCG↓, BAX↑, Bcl-2↓, PARP1↓, TumCCA↑, Apoptosis↑, cMyc↓, CDK4↓, CDK6↓, cycD1/CCND1↓, ChemoSen↑, miR-34a↑, miR-27a-3p↓,
5732- Buty,    GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon
- Study, CRC, NA
HCAR2↑, other↓, Apoptosis↑, HDAC↓, Bcl-2↓, Bcl-xL↓, cycD1/CCND1↓, DR5↑, NF-kB↓, GutMicro↑, SLC12A5↝,
5877- CA,    Carnosol induces apoptosis through generation of ROS and inactivation of STAT3 signaling in human colon cancer HCT116 cells
- in-vitro, CRC, HCT116
tumCV↓, Apoptosis↑, Casp9↑, Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, Bcl-xL↓, P53↓, MDM2↓, ROS↑, eff↓, STAT3↓, survivin↓, cycD1/CCND1↓,
5866- CA,    Carnosic acid inhibits STAT3 signaling and induces apoptosis through generation of ROS in human colon cancer HCT116 cells
- in-vitro, CRC, HCT116 - in-vitro, Colon, SW480 - in-vitro, Colon, HT29
tumCV↓, Apoptosis↑, P53↑, BAX↑, MDM2↓, Bcl-2↓, Bcl-xL↓, Casp9↑, Casp3↑, cl‑PARP↑, STAT3↓, survivin↓, cycD1/CCND1↓, CycD3↓, ROS↑, eff↓, eff↑,
1517- CAP,    Capsaicin Inhibits Multiple Bladder Cancer Cell Phenotypes by Inhibiting Tumor-Associated NADH Oxidase (tNOX) and Sirtuin1 (SIRT1)
- in-vitro, Bladder, TSGH8301 - in-vitro, CRC, T24/HTB-9
ENOX2↓, TumCCA↑, ERK↓, p‑FAK↓, p‑pax↓, TumCMig↓, EMT↓, SIRT1↓, Dose∅, ROS↑, MMP↓, Bcl-2↓, Bak↑, cl‑PARP↑, Casp3↑, SIRT1↓, ac‑P53↑, BIM↑, p‑RB1↓, cycD1/CCND1↓, Dose∅, β-catenin/ZEB1↓, N-cadherin↓, E-cadherin↑,
437- CUR,    Anti-cancer activity of amorphous curcumin preparation in patient-derived colorectal cancer organoids
- vitro+vivo, CRC, TCO1 - vitro+vivo, CRC, TCO2
cycD1/CCND1↓, cMyc↓, p‑ERK↓, CD44↓, CD133↓, LGR5↓, TumCCA↑, TumVol↓, CSCs↓,
4523- HNK,  MAG,  BA,    Honokiol-Magnolol-Baicalin Possesses Synergistic Anticancer Potential and Enhances the Efficacy of Anti-PD-1 Immunotherapy in Colorectal Cancer by Triggering GSDME-Dependent Pyroptosis
- in-vitro, CRC, HCT116 - in-vitro, CRC, LoVo - in-vivo, CRC, HCT116
AntiCan↑, eff↑, TumCP↓, TumCCA↓, cycD1/CCND1↓, Pyro↑, Apoptosis↑, cl‑GSDME↑, Bcl-2↓, Cyt‑c↑, Casp9↑, TumCG↓,
1182- MushCha,    Ergosterol peroxide from Chaga mushroom (Inonotus obliquus) exhibits anti-cancer activity by down-regulation of the β-catenin pathway in colorectal cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT-29 - in-vitro, CRC, SW-620 - in-vitro, CRC, DLD1
Apoptosis↑, TumCG↓, FASN↓, β-catenin/ZEB1↓, cMyc↓, cycD1/CCND1↓, CDK8↓, Ki-67↓,
1227- OLST,    Anti-Obesity Drug Orlistat Alleviates Western-Diet-Driven Colitis-Associated Colon Cancer via Inhibition of STAT3 and NF-κB-Mediated Signaling
- in-vivo, CRC, NA
OS↑, Inflam↓, TumCG↓, STAT3↓, NF-kB↓, β-catenin/ZEB1↓, Slug↓, XIAP↓, CDK4↓, cycD1/CCND1↓, Bcl-2↓,
58- QC,  doxoR,    Quercetin induces cell cycle arrest and apoptosis in CD133+ cancer stem cells of human colorectal HT29 cancer cell line and enhances anticancer effects of doxorubicin
- in-vitro, CRC, HT-29 - in-vitro, NA, CD133+
Bcl-2↓, TumCCA↑, CD133↓, CSCs↓, ChemoSen↑, CycB/CCNB1↑, cycE/CCNE↓, cycD1/CCND1↓, E2Fs↓,
2230- SK,    Shikonin induces ROS-based mitochondria-mediated apoptosis in colon cancer
- in-vitro, CRC, HCT116 - in-vivo, NA, NA
TumCG↓, Bcl-2↓, ROS↑, Bcl-xL↓, MMP↓, Casp↑, selectivity↑, cycD1/CCND1↓, TumCCA↑, eff↓,
3047- SK,    Shikonin suppresses colon cancer cell growth and exerts synergistic effects by regulating ADAM17 and the IL-6/STAT3 signaling pathway
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, p‑STAT3↓, ADAM17↓, Apoptosis↑, Casp3↑, cl‑PARP↑, cycD1/CCND1↓, cycE/CCNE↓, TumCCA↑, JAK1?, p‑JAK1↓, p‑JAK2↓, p‑eIF2α↑, eff↓, ROS↑, IL6↓,
1017- SSE,    Selenite induces apoptosis in colorectal cancer cells via AKT-mediated inhibition of β-catenin survival axis
- vitro+vivo, CRC, NA
Akt↓, β-catenin/ZEB1↓, cycD1/CCND1↓, survivin↓, Apoptosis↑, ROS↑,
3413- TQ,    Thymoquinone induces apoptosis in human colon cancer HCT116 cells through inactivation of STAT3 by blocking JAK2- and Src‑mediated phosphorylation of EGF receptor tyrosine kinase
- in-vitro, CRC, HCT116
tumCV↓, Apoptosis↓, BAX↑, Bcl-2↓, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, STAT3↓, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, EGFR↓, ROS↑,
3397- TQ,    Thymoquinone: A Promising Therapeutic Agent for the Treatment of Colorectal Cancer
- Review, CRC, NA
ChemoSen↑, *Half-Life↝, *BioAv↝, *antiOx↑, *Inflam↓, *hepatoP↑, TumCP↓, TumCCA↑, Apoptosis↑, angioG↑, selectivity↑, JNK↑, p38↑, p‑NF-kB↑, ERK↓, PI3K↓, PTEN↑, Akt↓, mTOR↓, EMT↓, Twist↓, E-cadherin↓, ROS⇅, *Catalase↑, *SOD↑, *GSTA1↑, *GPx↑, *PGE2↓, *IL1β↓, *COX2↓, *MMP13↓, MMPs↓, TumMeta↓, VEGF↓, STAT3↓, BAX↑, Bcl-2↑, Casp9↑, Casp7↑, Casp3↑, cl‑PARP↑, survivin↓, cMyc↓, cycD1/CCND1↓, p27↑, P21↑, GSK‐3β↓, β-catenin/ZEB1↓, chemoP↑,
1820- VitK3,    Vitamin K3 (menadione) suppresses epithelial-mesenchymal-transition and Wnt signaling pathway in human colorectal cancer cells
- in-vitro, CRC, SW480 - in-vitro, CRC, SW-620
selectivity↑, TumCI↓, TumCMig↓, EMT↓, E-cadherin↑, ZO-1↑, N-cadherin↓, Vim↓, Zeb1↓, MMP2↓, MMP9↓, TOPflash↓, β-catenin/ZEB1↓, p300↓, cycD1/CCND1↓, TumCCA↑,

Showing Research Papers: 1 to 24 of 24

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 24

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ENOX2↓, 1,   ROS↑, 8,   ROS⇅, 1,  

Mitochondria & Bioenergetics ⓘ

CDC2↓, 1,   MMP↓, 3,   XIAP↓, 2,  

Core Metabolism/Glycolysis ⓘ

ACC↑, 1,   AMPK↑, 1,   AMPK↝, 1,   cMyc↓, 6,   FASN↓, 1,   glucose↓, 1,   Glycolysis↓, 1,   lactateProd↓, 1,   PKM2↓, 1,   SIRT1↓, 2,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↓, 1,   Apoptosis↑, 11,   Bak↑, 1,   BAX↑, 5,   Bcl-2↓, 12,   Bcl-2↑, 1,   Bcl-xL↓, 6,   BIM↑, 1,   Casp↑, 1,   Casp3↑, 6,   cl‑Casp3↑, 1,   Casp7↑, 2,   Casp8↑, 1,   Casp9↑, 6,   Cyt‑c↑, 2,   DR5↑, 1,   cl‑GSDME↑, 1,   IAP1↓, 2,   JNK↑, 1,   MDM2↓, 2,   p27↑, 3,   p38↑, 1,   Pyro↑, 1,   survivin↓, 9,   Telomerase↓, 1,  

Kinase & Signal Transduction ⓘ

HCAR2↑, 1,   Sp1/3/4↓, 1,  

Transcription & Epigenetics ⓘ

miR-27a-3p↓, 2,   other↓, 1,   tumCV↓, 3,  

Protein Folding & ER Stress ⓘ

p‑eIF2α↑, 1,   GRP78/BiP↓, 1,  

DNA Damage & Repair ⓘ

P53↓, 1,   P53↑, 2,   ac‑P53↑, 1,   cl‑PARP↑, 6,   PARP1↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 4,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 24,   CycD3↓, 1,   cycE/CCNE↓, 4,   E2Fs↓, 1,   P21↑, 4,   p‑RB1↓, 2,   TumCCA↓, 1,   TumCCA↑, 11,  

Proliferation, Differentiation & Cell State ⓘ

CD133↓, 3,   CD44↓, 2,   CDK8↓, 1,   CSCs↓, 3,   EMT↓, 4,   ERK↓, 2,   p‑ERK↓, 1,   GSK‐3β↓, 1,   HDAC↓, 1,   Let-7↑, 1,   LGR5↓, 1,   miR-34a↑, 2,   mTOR↓, 2,   mTOR↝, 1,   p300↓, 1,   PI3K↓, 1,   PTEN↑, 1,   STAT3↓, 5,   p‑STAT3↓, 3,   TOPflash↓, 1,   TumCG↓, 12,  

Migration ⓘ

5LO↓, 1,   CD31↓, 1,   E-cadherin↓, 2,   E-cadherin↑, 3,   p‑FAK↓, 1,   FTO↑, 1,   Ki-67↓, 4,   miR-200b↑, 1,   MMP2↓, 2,   MMP9↓, 4,   MMPs↓, 2,   N-cadherin↓, 2,   p‑pax↓, 1,   Slug↓, 1,   TumCI↓, 2,   TumCMig↓, 3,   TumCP↓, 4,   TumMeta↓, 2,   Twist↓, 1,   Vim↓, 2,   Zeb1↓, 1,   ZO-1↑, 1,   β-catenin/ZEB1↓, 7,  

Angiogenesis & Vasculature ⓘ

angioG↑, 1,   EGFR↓, 3,   VEGF↓, 4,  

Barriers & Transport ⓘ

SLC12A5↝, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 4,   CXCR4↓, 2,   HCAR2↑, 1,   ICAM-1↓, 1,   IL6↓, 1,   Inflam↓, 2,   JAK1?, 1,   p‑JAK1↓, 1,   p‑JAK2↓, 2,   NF-kB↓, 5,   p‑NF-kB↑, 1,   p65↓, 1,   PGE2↓, 1,  

Cellular Microenvironment ⓘ

ADAM17↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 2,  

Drug Metabolism & Resistance ⓘ

BioAv↑, 1,   ChemoSen↑, 5,   Dose∅, 2,   eff↓, 4,   eff↑, 2,   eff↝, 1,   selectivity↑, 3,  

Clinical Biomarkers ⓘ

ascitic↓, 1,   EGFR↓, 3,   GutMicro↑, 2,   IL6↓, 1,   Ki-67↓, 4,  

Functional Outcomes ⓘ

AntiCan↑, 1,   chemoP↑, 1,   OS↑, 1,   TumVol↓, 3,   Weight∅, 1,  
Total Targets: 145

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   Catalase↑, 1,   GPx↑, 1,   GSTA1↑, 1,   SOD↑, 1,  

Migration ⓘ

MMP13↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL1β↓, 1,   Inflam↓, 2,   PGE2↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   BioAv↝, 1,   Half-Life↝, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  
Total Targets: 17

Scientific Paper Hit Count for: cycD1/CCND1, cyclin D1 pathway
4 Berberine
4 Boswellia (frankincense)
2 Curcumin
2 Carnosic acid
2 Shikonin
2 Thymoquinone
1 Betulinic acid
1 Chemotherapy
1 Butyrate
1 Capsaicin
1 Honokiol
1 Magnolol
1 Baicalin
1 Mushroom Chaga
1 Orlistat
1 Quercetin
1 doxorubicin
1 Selenite (Sodium)
1 VitK3,menadione
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:6  Cells:%  prod#:%  Target#:73  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page